Exponential Biotherapies, Inc. develops therapeutics to attenuate overreactions of the immune system that may lead to severe organ damage and death.
The company’s lead product targets acute renal failure following surgery, an important cause of death in hospital intensive care units.
Portfolio: MedSciences Capital B.V.
Current product development stage: phase II clinical trials.
